YOL153C Antibody

What is the YOL153C gene product and what role does it play in cellular function?

YOL153C encodes Pac2, a tubulin chaperone E protein in yeast that binds to both microtubules and proteasomes. Pac2 plays a novel role in the misfolded protein stress response based on its ability to interact with both the microtubule cytoskeleton and proteasomes . This dual interaction capability positions Pac2 as a key component in cellular quality control mechanisms. Functionally, it facilitates proper microtubule assembly while also participating in protein degradation pathways, making it essential for maintaining cellular homeostasis. The protein contains both a CAP-Gly domain involved in tubulin binding and a UbL (ubiquitin-like) domain that mediates interactions with proteasomal components.

How does the structure of YOL153C/Pac2 antibody influence its binding specificity?

Antibodies against YOL153C/Pac2 typically target specific epitopes on the protein structure. The binding specificity is determined by the complementarity-determining regions (CDRs) of the antibody, particularly the CDR H3 region which contains critical binding motifs . Similar to other well-characterized antibodies, anti-YOL153C antibodies may contain specific amino acid sequences in their variable regions that facilitate binding to conserved structural elements of the target protein. The three-dimensional arrangement of these binding domains creates a precise interface that determines specificity and affinity. Effective anti-YOL153C antibodies must maintain structural integrity to preserve this binding interface, which can be influenced by buffer conditions, temperature, and other experimental variables.

What are the differences between polyclonal and monoclonal antibodies for YOL153C/Pac2 research?

Polyclonal antibodies against YOL153C/Pac2 target multiple epitopes and are generated from multiple B cell lineages, providing broad recognition but potential variation between lots. Monoclonal antibodies, which can be generated using recombinant techniques similar to those used for therapeutic antibodies, offer greater consistency and specificity by targeting a single epitope .

For YOL153C research, the choice between these types depends on the experimental goals:

The production of recombinant monoclonal antibodies allows for greater flexibility during production and more opportunities for optimization, such as affinity maturation and conversion to different formats .

What is the optimal protocol for immunoprecipitation using YOL153C/Pac2 antibodies?

For immunoprecipitation (IP) of YOL153C/Pac2, the following protocol has been optimized based on experimental methods described in the literature:

• Cell extraction preparation:

  • Harvest 50 ml of logarithmic yeast culture

  • Prepare 300 μl of cell extract with protein concentration of approximately 80 μg/μl

  • Use 200 μl of extract for each immunoprecipitation reaction

• Antibody incubation:

  • Add anti-GFP antibodies at 1:200 dilution for GFP-tagged Pac2 constructs

  • Alternatively, use specific anti-Pac2 antibodies at appropriate dilutions

  • Incubate at 4°C with gentle rotation for 2-4 hours

• Protein capture:

  • Add 30 μl of 50% Protein A-Sepharose slurry

  • Continue incubation at 4°C for 1 hour with gentle rotation

  • Collect immunoprecipitates by centrifugation at 12,000 g

• Washing and elution:

  • Wash beads 3-5 times with cold lysis buffer

  • Elute bound proteins with SDS-PAGE sample buffer

  • Analyze by Western blotting using appropriate antibodies

This protocol has been shown to effectively isolate Pac2 and its interacting partners, including proteasomal components and tubulin, allowing for analysis of protein-protein interactions in the context of cellular stress responses.

How should Western blotting conditions be optimized when using YOL153C/Pac2 antibodies?

Western blotting with YOL153C/Pac2 antibodies requires specific optimization to achieve clear and reproducible results:

• Sample preparation:

  • For TCA precipitation: add TCA to 10% with 10 min incubation on ice

  • Centrifuge at 12,000 g for 10 min, wash with cold acetone

  • Dissolve protein pellets in sample buffer (typically 30 μl)

• Gel electrophoresis and transfer:

  • Use fresh SDS-PAGE gels (8-12% depending on desired separation)

  • Transfer to PVDF or nitrocellulose membrane at constant voltage (100V for 1 hour or 30V overnight)

• Antibody dilutions and incubation:

  • Primary antibody: Anti-GFP at 1:1,000 for GFP-tagged Pac2 constructs

  • For ubiquitylation studies: Anti-ubiquitin antibodies at 1:5,000

  • Secondary antibodies: Goat anti-mouse or goat anti-rabbit at 1:1,000

• Signal detection optimization:

  • For low abundance proteins, use enhanced chemiluminescence with longer exposure times

  • For quantitative analysis, consider fluorescent secondary antibodies and digital imaging

• Controls:

  • Include wild-type and mutant samples (such as pac2Δ extracts)

  • For ubiquitylation studies, include rpn10Δ samples to assess proteasomal degradation efficiency

This approach allows for detection of both native Pac2 and modified forms, including ubiquitylated species and protein complexes.

What methods can detect interactions between YOL153C/Pac2 and the proteasome?

Several complementary approaches can effectively detect and characterize interactions between YOL153C/Pac2 and proteasomal components:

• Co-immunoprecipitation (Co-IP):

  • Immunoprecipitate GFP-tagged Pac2 constructs with anti-GFP antibodies

  • Detect proteasomal subunits (such as Rpn10, Rpn12, Pre6) in the immunoprecipitates

  • Use appropriate antibody dilutions: anti-Rpn10 (1:10,000), anti-Rpn12 (1:10,000), anti-Pre6 (1:1,000)

• Pull-down assays:

  • Generate recombinant GST-tagged proteasomal subunits

  • Incubate with cell extracts containing wild-type or mutant Pac2

  • Analyze binding using GSH beads followed by Western blotting

• Yeast two-hybrid analysis:

  • Construct fusion proteins with Pac2 and proteasomal components

  • Assess direct protein interactions through reporter gene activation

• Confocal microscopy:

  • Visualize co-localization of fluorescently-tagged Pac2 and proteasome components

  • Perform FRET analysis to assess proximity in living cells

• Mass spectrometry:

  • Perform immunoprecipitation of Pac2 complexes

  • Identify associated proteins through peptide mass fingerprinting

Research has demonstrated that the UbL domain of Pac2 is crucial for interaction with the proteasome, as deletion constructs (GFPPac2ΔUbL) show reduced binding to proteasomal components .

How can structural biology techniques be applied to study YOL153C/Pac2 antibody binding mechanisms?

Structural biology techniques offer powerful insights into the binding mechanisms of YOL153C/Pac2 antibodies:

• Cryo-electron microscopy (cryo-EM):

  • Can determine the structure of antibody-antigen complexes at near-atomic resolution

  • Allows visualization of multiple binding configurations without crystallization

  • Has been successfully used to characterize complex antibody binding modes in other systems

  • Enable visualization of how multiple antibodies might bind simultaneously to different domains of Pac2

• X-ray crystallography:

  • Provides atomic-level resolution of antibody-antigen interfaces

  • Can reveal critical contact residues and binding energetics

  • Has been used to identify functional motifs like YYDRxG in antibody CDR regions

• Hydrogen-deuterium exchange mass spectrometry (HDX-MS):

  • Maps dynamic conformational changes upon antibody binding

  • Reveals epitopes through differential solvent exposure measurements

  • Can identify allosteric effects of antibody binding on distant protein regions

• Surface plasmon resonance (SPR):

  • Measures binding kinetics and affinity constants

  • Characterizes the on/off rates of antibody-antigen interactions

  • Provides thermodynamic parameters of binding events

These methodologies can reveal how anti-YOL153C antibodies recognize specific domains like the CAP-Gly or UbL regions, potentially identifying conserved binding motifs similar to the YYDRxG patterns observed in other antibody systems .

How can YOL153C/Pac2 antibodies be used to study protein degradation pathways?

YOL153C/Pac2 antibodies serve as powerful tools for investigating protein degradation pathways due to Pac2's dual role in microtubule dynamics and proteasomal interactions:

• Monitoring ubiquitylation states:

  • Immunoprecipitate Pac2 and probe with anti-ubiquitin antibodies

  • Compare ubiquitylation patterns in wild-type and mutant backgrounds (pac2Δ, rpn10Δ)

  • Assess the role of specific domains (UbL, CAP-Gly) in ubiquitylation efficiency

• Analyzing protein half-life:

  • Perform cycloheximide chase experiments with Western blot detection

  • Compare stability of Pac2 in different genetic backgrounds (cdc53Δ mutants show partial stabilization)

  • Quantify degradation kinetics of wild-type versus mutant Pac2 proteins

• SCF complex interactions:

  • Study binding of Pac2 to SCF components (like Cdc53/Cullin1)

  • Assess the role of the UbL domain in mediating these interactions

  • Investigate how SCF-mediated ubiquitylation contributes to Pac2 turnover

• Stress-response studies:

  • Monitor changes in Pac2 levels and modifications during cellular stress

  • Investigate the coordination between microtubule dynamics and protein degradation

  • Assess how Pac2 mediates cross-talk between cytoskeletal and proteolytic systems

These approaches have revealed that while the UbL domain of Pac2 is important for interaction with SCF components, Pac2 can be ubiquitylated independently of this domain, suggesting complex regulation of its degradation .

What approaches can be used to develop YOL153C/Pac2 antibodies with improved specificity?

Developing highly specific YOL153C/Pac2 antibodies requires sophisticated approaches:

• Epitope-guided selection strategies:

  • Target unique regions of Pac2 that lack homology to other proteins

  • Focus on functionally important domains like the CAP-Gly or UbL regions

  • Design peptide antigens that represent exposed regions of the native protein

• Recombinant antibody library technology:

  • Utilize HuCAL® or similar recombinant antibody libraries

  • Employ phage display to select high-affinity binders

  • Incorporate counter-selection strategies to eliminate cross-reactive clones

• Affinity maturation:

  • Introduce directed mutations in CDR regions

  • Screen for variants with enhanced binding properties

  • Select for optimal on/off rates rather than just binding strength

• Validation against knockout controls:

  • Test antibody specificity against pac2Δ samples

  • Perform competition assays with purified antigen

  • Evaluate cross-reactivity with related proteins

• Strategic antibody combinations:

  • Develop non-competing antibody pairs targeting different epitopes

  • Create bispecific formats for enhanced specificity

  • Implement sandwich assay formats for improved detection specificity

Selection of antibodies can be guided to generate different binding modes, similar to anti-idiotypic antibody development strategies where Type 1 (inhibitory), Type 2 (non-inhibitory), and Type 3 (complex-specific) antibodies are developed for different applications .

What are common issues in immunoprecipitation with YOL153C/Pac2 antibodies and how can they be resolved?

Researchers frequently encounter several challenges when performing immunoprecipitation with YOL153C/Pac2 antibodies:

• Low yield of target protein:

  • Problem: Insufficient protein recovery despite confirmed expression

  • Solution: Optimize lysis conditions (50 ml of logarithmic culture for 300 μl extract); increase antibody concentration (use 1:200 dilution for anti-GFP); extend incubation time with gentle rotation

• High background in Western blot analysis:

  • Problem: Non-specific bands obscuring results

  • Solution: Include additional washing steps; use more stringent wash buffers; include competing proteins (BSA) in wash buffers; optimize antibody dilutions (1:1,000-1:10,000 for Western blot detection)

• Inconsistent co-immunoprecipitation of interacting partners:

  • Problem: Variable detection of proteasomal components or tubulin

  • Solution: Stabilize interactions with reversible crosslinkers; adjust salt concentration in buffers; optimize detergent type and concentration; ensure proper protein induction (overnight growth in minimal medium with 2% galactose followed by 1:3 dilution and 1.5 h growth)

• Degradation of target protein during extraction:

  • Problem: Multiple lower molecular weight bands or smears

  • Solution: Include protease inhibitors; perform extraction at 4°C; use freshly prepared buffers; add deubiquitinating enzyme inhibitors for ubiquitylation studies

• Inconsistent ubiquitylation detection:

  • Problem: Variable detection of ubiquitylated species

  • Solution: Use rpn10Δ mutants to stabilize ubiquitylated proteins; perform TCA precipitation to preserve modifications; use anti-ubiquitin antibodies at 1:5,000 dilution

These troubleshooting approaches have been validated in published protocols for studying Pac2 and its interactions with the proteasome and microtubule cytoskeleton.

How do genetic backgrounds affect YOL153C/Pac2 antibody experiments?

The genetic background of yeast strains significantly impacts YOL153C/Pac2 antibody experiments in ways that must be considered for experimental design:

• Wild-type vs. knockout controls:

  • pac2Δ strains are essential negative controls for antibody specificity

  • Comparison with wild-type demonstrates specific vs. non-specific signals

  • pac2Δ backgrounds allow exclusive detection of ectopically expressed constructs

• Proteasome pathway mutants:

  • rpn10Δ mutants accumulate ubiquitylated proteins, enhancing detection

  • cdc53Δ mutants (defective in SCF E3 ligase) show partial stabilization of Pac2

  • These backgrounds help dissect specific degradation pathways

• Expression system considerations:

  • GAL promoter systems require specific induction protocols (overnight growth in minimal medium with 2% galactose)

  • Expression levels affect complex formation and detection sensitivity

  • Induction timing can influence post-translational modifications

• Tagging strategies impact:

  • GFP-tagged constructs may have altered stability or localization

  • Different tags (myc, GFP) require specific antibody detection protocols

  • Consider tag position (N- or C-terminal) based on domain structure

• Strain-specific differences:

  • Growth conditions may need adjustment for different genetic backgrounds

  • Extract preparation protocols may require optimization for specific strains

  • Antibody concentrations may need titration for different expression systems

Research has shown that in pac2Δ backgrounds, GFPPac2ΔUbL shows different ubiquitylation patterns compared to wild-type backgrounds, highlighting the importance of genetic context in interpreting experimental results .

What considerations are important when analyzing domain-specific functions of YOL153C/Pac2 using antibodies?

When using antibodies to study domain-specific functions of YOL153C/Pac2, several critical considerations must be addressed:

Experimental evidence shows that while the UbL domain is critical for interaction with SCF components like Cdc53, it is not essential for all ubiquitylation of Pac2, suggesting complex regulation involving multiple domains and pathways .

How can combination antibody approaches be applied to YOL153C/Pac2 research?

Combination antibody approaches, similar to those developed for viral research, offer promising strategies for YOL153C/Pac2 studies:

• Multiple non-competing antibodies:

  • Target different epitopes on Pac2 simultaneously

  • Combine antibodies against CAP-Gly, UbL, and other domains

  • Enhance detection sensitivity and specificity similar to viral neutralization strategies

• Structural mapping of binding sites:

  • Use cryo-EM or X-ray crystallography to confirm non-overlapping binding

  • Create models of multi-antibody complexes with Pac2

  • Optimize antibody combinations based on structural data

• Functional antibody combinations:

  • Pair domain-blocking with non-blocking detection antibodies

  • Develop sandwich assay formats with enhanced specificity

  • Create bispecific antibodies targeting both Pac2 and interacting partners

• Triple antibody combinations:

  • Similar to approaches used in viral research, develop three non-competing antibodies

  • Target all major functional domains simultaneously

  • Create robust detection systems resilient to conformational changes

• Adaptable antibody toolkits:

  • Develop modularity in antibody-based detection systems

  • Allow customization for specific experimental needs

  • Enable multiplexed analysis of protein complexes

Research with viral antigen systems has demonstrated that triple antibody combinations targeting non-overlapping epitopes provide superior coverage and resistance to escape mutations, a principle that could be adapted for studying dynamic proteins like Pac2 .

What approaches integrate antibody-based detection with advanced microscopy for YOL153C/Pac2 visualization?

Integrating antibody-based detection with advanced microscopy creates powerful approaches for visualizing YOL153C/Pac2 dynamics:

• Super-resolution microscopy techniques:

  • Stimulated emission depletion (STED) microscopy for visualizing Pac2 association with microtubules

  • Single-molecule localization microscopy (PALM/STORM) for tracking individual Pac2 molecules

  • Structured illumination microscopy (SIM) for visualizing Pac2-proteasome interactions

• Live-cell imaging strategies:

  • Combine fluorescently-tagged anti-Pac2 antibody fragments with live cell imaging

  • Use FRET-based biosensors to monitor Pac2 conformational changes

  • Employ split-GFP complementation to visualize specific protein-protein interactions

• Correlative light and electron microscopy (CLEM):

  • Localize Pac2 at light microscopy level then examine ultrastructure by EM

  • Use immunogold labeling with anti-Pac2 antibodies for precise localization

  • Analyze Pac2 distribution relative to cellular compartments at nanometer resolution

• Expansion microscopy:

  • Physical expansion of cellular structures for improved resolution

  • Use antibodies to label Pac2 in expanded specimens

  • Achieve super-resolution imaging on conventional microscopes

• Light sheet microscopy:

  • Reduced phototoxicity for long-term imaging of Pac2 dynamics

  • Capture rapid turnover and trafficking events

  • Visualize Pac2 behavior during cellular stress responses

These advanced imaging approaches, combined with specific antibody detection systems, enable researchers to visualize the dynamic interplay between Pac2, the microtubule cytoskeleton, and the proteasome degradation machinery with unprecedented spatial and temporal resolution.